



Published in final edited form as:

Biochemistry. 1997 March 18; 36(11): 3126–3132. doi:10.1021/bi962065d.

Conversion of the Allosteric Regulatory Patterns of Aspartate Transcarbamoylase by Exchange of a Single β -Strand between Diverged Regulatory Chains[†]

Leyuan Liu, Melinda E. Wales, and James R. Wild

Department of Biochemistry & Biophysics, The Texas A&M University System, College Station, Texas 77843-2128

Abstract

Although structurally very similar, the aspartate transcarbamoylases (ATCase) of *Serratia marcescens* and *Escherichia coli* differ in both regulatory and catalytic characteristics. Most notably, CTP stimulates the catalytic activity of the *S. marcescens* ATCase and CTP/UTP inhibitory synergism has been lost. These allosteric characteristics contradict the traditional logic developed from the *E. coli* enzyme in which CTP and UTP function together as end products of the pyrimidine pathway to allosterically control the catalytic activity. In this study, five divergent residues (r93–r97) of the regulatory polypeptide of the *S. marcescens* enzyme have been replaced with their *E. coli* counterparts. These residues correspond to the S5' β -strand of the allosteric effector binding domain at the junction of the allosteric and zinc domains of the regulatory polypeptide. In spite of the fact that the chimeric ATCase (SM:rS5'ec) retained 455 out of 460 amino acids of the *S. marcescens* enzyme, it possessed characteristics similar to those of the *E. coli* enzyme: (1) the [Asp]_{0.5} decreased from 40 to 5 mM; (2) ATP activation of the enzyme was greatly reduced; (3) CTP was converted from a strong activator to a strong inhibitor; and (4) the synergistic inhibition by CTP and UTP was restored. The S5' β -strand is located at the outer surface of a five-stranded β -sheet of the allosteric domain, providing a potential structural mechanism defining the allostery of this enzyme.

Aspartate transcarbamoylase (EC 2.1.3.2; ATCase)¹ provides the first unique step of the pathway for *de novo* pyrimidine biosynthesis by catalyzing the condensation of L-aspartate with carbamoyl phosphate to form carbamoyl aspartate and phosphate, ultimately leading to the end products UTP and CTP (Jones et al., 1995; Reichard & Hanshoff, 1956). The regulation of this transcarbamoylation varies from substrate channeling in multienzyme complexes to allosteric control of independent enzymes composed of distinct catalytic and regulatory subunits in various biological systems. Multiple structures of the *Escherichia coli* (Ec) ATCase (2c₃:3r₂)² have been characterized by X-ray crystallography [Gouaux et al.,

[†]This research has been supported by grants from the Robert A. Welch Foundation (A915) and the NIH (GM33191). L.L. was a TAMU Regent's Graduate Fellow.

© 1997 American Chemical Society

Correspondence to: James R. Wild.

¹Abbreviations: ATCase, aspartate transcarbamoylase; ATP, adenosine 5'-triphosphate; CTP, cytidine 5'-triphosphate; UTP, uridine 5'-triphosphate; NTP, nucleoside triphosphate; [Asp]_{0.5}, aspartate concentration at half-maximal velocity; Ec, *Escherichia coli*; Sm, *Serratia marcescens*.

²Nomenclature: SM:rS5'ec, designation of the chimera in which the S5' β -strand in the regulatory polypeptide of the Sm ATCase has been replaced with the Ec sequence; r, regulatory polypeptide; c, catalytic polypeptide; 2c₃:3r₂, two catalytic subunits, each containing three catalytic polypeptides, and three regulatory subunits, each containing two regulatory polypeptides; r1 or c2, the non-subscripted number represents the polypeptide designation (i.e., regulatory polypeptide 1 and catalytic polypeptide 2); R and C, the regulatory dimeric and catalytic trimeric subunits, respectively, with subscripts indicating their origins; for example, C_{ec}:R_{sm} describes a hybrid composed of the catalytic subunits from Ec and regulatory subunits from Sm.

1990; Stevens et al., 1990; Ke et al., 1988; Kosman et al., 1993; for review see Lipscomb (1994)], and the relationship between structure and function has been intensively investigated using single-site-directed mutagenesis [for review see Kantrowitz and Lipscomb (1990); Stevens et al., 1991].

The ATCase holoenzymes from *Ec* and other enteric bacteria are expressed from the *pyrLBI* operons. The *pyrB* and *pyrI* cistrons encode the catalytic and regulatory polypeptides, respectively. Three catalytic polypeptides associate to form a functional catalytic subunit (trimer, c_3), and two regulatory polypeptides form a regulatory subunit (dimer, r_2). The holoenzyme is composed of two catalytic subunits and three regulatory subunits ($2c_3:3r_2$). Each of the catalytic polypeptides is composed of a carbamoyl phosphate binding domain (CP domain) and an aspartate binding domain (Asp domain), while each regulatory polypeptide is folded into an allosteric effector binding domain (Allo domain) and a zinc binding domain (Zn domain). The active sites are found at the interfaces of the Asp and CP domains of the catalytic trimers, 60 Å away from the nucleotide binding sites which are located adjacent to the five-stranded β -sheets of the Allo domains and connected to the Zn domains through the S5' β -strand (Figure 1).

When substrate ligands bind to the native *Ec* ATCase, there is a conformational change from a less active “T-state” to the more active, open “R-state” (Schachman et al., 1988; Lipscomb, 1994). As the T \rightarrow R transition occurs, the catalytic trimers move apart by 12 Å, and the catalytic and regulatory subunits rotate 10° and 15° above their axes of symmetry, respectively (Krause et al., 1987). The holoenzyme exhibits both homotropic and heterotropic allosteric regulation, by which the positive cooperativity of binding of aspartate can be modulated (Gerhart & Schachman, 1968; Bethell et al., 1968). The nucleotide effectors competitively bind to the r_2 dimers and either activate (ATP) or inhibit (CTP, CTP + UTP) the formation of carbamoyl aspartate (Gerhart & Pardee, 1962; Wild et al., 1989).

The ATCase from *Serratia marcescens* (*Sm*) has the same dodecameric structure, $2c_3:3r_2$, as the *Ec* enzyme and shares 85% and 76% amino acid identity within their catalytic and regulatory polypeptides, respectively (Beck et al., 1989; this study). The regulatory polypeptide of *Sm* ATCase has 154 amino acids, one more than the *Ec*; however, a direct comparison of the sequences of the *Sm* and *Ec* regulatory polypeptides indicates there are only 37 amino acid differences between the two. The most divergent regions are involved in the minor $r1:c1$ interface ($r130$'s region) and the Zn:Allo domain junction ($r100$'s region) (Beck et al., 1989; Wild et al., 1990; Wild & Wales, 1990; and Figure 2). Most of the residues involved in the nucleotide binding sites and all inter- and intrasubunit interfaces ($r1:c1$, $r1:c4$, $r1:r6$, and Allo:Zn) are conserved between the two enzymes (Gouaux et al., 1990; Beck et al., 1989). In spite of these apparent structural similarities, the two enzymes differ in both regulatory and catalytic characteristics. Most notably, CTP activates the catalytic activity of the *Sm* ATCase, and the CTP + UTP inhibitory synergism is lost. This allosteric pattern is contrary to the traditional logic of the *Ec* ATCase where CTP, the end product of the pathway, feedback inhibits 50–60% of the catalytic activity of the enzyme, and the combination of CTP and UTP inhibits 90–95%. A hybrid ATCase assembled *in vivo* with the catalytic subunits from *Ec* and the regulatory subunits from *Sm* ($C_{ec}:R_{sm}$) exhibited heterotropic responses characteristics of the native *Sm* holoenzyme (ATP and CTP activation; Shanley et al., 1984; Beck et al., 1989). In contrast, the reverse hybrid enzyme ($C_{sm}:R_{ec}$), utilizing the *Sm* catalytic subunits and the *Ec* regulatory subunits, exhibited the heterotropic responses characteristic of *Ec* (Shanley et al., 1984; Beck et al., 1989). These hybrids, along with other interspecies hybrids, have verified the hypothesis that the allosteric responses of the ATCase holoenzyme are determined exclusively by the controlling regulatory subunits (Wild et al., 1990; Wild & Wales, 1990; Wales & Wild, 1991).

The structural similarity and the functional divergence of these two enzymes provide an opportunity to directly address the role of specific structural regions in allosteric regulation. In this study, a chimeric enzyme has been constructed in which the S5' β -sheet of the Sm enzyme was replaced by that of the Ec enzyme. The resulting chimeric ATCase displays allosteric patterns similar to those of the native Ec enzyme (ATP activation, CTP inhibition, and CTP + UTP synergistic inhibition). These results suggest that the nonconserved residues r93–r97 are critical to defining the diverged allosteric function and that the nature of the allosteric response is directly modulated by this region.

EXPERIMENTAL PROCEDURES

Site-Directed Mutagenesis

Site-directed mutagenesis was performed with double-stranded plasmid according to the protocol developed by Deng and Nickoloff (1992) with a 1 to 1000 molar ratio of template to primer. The mutagenesis primer (33-mer) replaced the coding sequence for residues from r93 to r97 in the regulatory polypeptide with that represented in the Ec sequence, and the selection primer removed a unique *NcoI* site located in the *pyrB* gene, without changing the encoded amino acid sequence. Both primers were synthesized by GIBCO BRL. After mutagenesis, the resulting plasmid pool was transformed into Ec strain, *BMH71-18 mutS*, amplified overnight, reisolated using the Wizard miniprep column from Promega, and extensively digested with *NcoI*. The digested plasmid pool was transformed into Ec strain, EK1104 (*ara*, Δ *pro-lac*, *strA*, *thi*, *pyrBI*, *pyrF*⁺, *rpsL*; Nowlan & Kantrowitz, 1985), and plated on LB medium with 40 mg/L ampicillin. The resulting colonies were screened by restriction mapping, and suspected chimeras were verified by sequencing. Following the positive identification of the desired chimera, the entire *pyrBI* operon was sequenced using the Sequenase version 2.0 DNA sequencing kit from USB to demonstrate that there were no other mutations occurring in the operon.

Enzyme Purification

Plasmid pPBh200-sm was created from PBh5109-sm (Beck et al., 1989) by inserting the 2.2 kb *EcoRI/HindIII* fragment from PBh5109-sm into pBR322. The plasmids containing the native (pPBh200-sm for Sm, pPBh105-ec for Ec; Roof et al., 1982) or chimera *pyrBI* operon were transformed into EK1104 and grown in minimal medium (TF medium) supplemented as previously described (Wales et al., 1988). The overexpressed holoenzyme was purified to homogeneity as previously described (Wales et al., 1988) with the following modifications: elimination of the pI precipitation, and the addition of ion-exchange chromatography (Hiload 26/10 Q Sepharose Fast Flow from Pharmacia LKB Biotechnology) with a salt gradient from 0.15 to 0.5 M KCl, and a final chromatographic step on a molecular sieve column (Superdex 200 prep grade from Pharmacia LKB Biotechnology). Purity of the enzyme was verified by both SDS-PAGE and native gel electrophoresis using Coomassie and silver staining (Smith, 1988; Sasse, 1988). The concentration of the holoenzyme was determined by absorbance at wavelength 280 nm using an extinction coefficient of 0.59 (Gerhart & Holobek, 1967).

Enzymatic Assays

ATCase activity was determined according to the colorimetric assay of Prescott and Jones (1969). Aspartate requirements were determined in the presence of a saturating concentration of carbamoyl phosphate (4.8 mM). Effector responses of the enzyme were determined in the presence of 2 mM ATP (4 mM for the native Sm ATCase), 2 mM CTP, 2 mM UTP, or 2 mM CTP plus 2 mM UTP (all are the saturating concentration at both the [Asp]_{0.5} and half of the [Asp]_{0.5} for aspartate). All enzyme activity assays were performed at 30 °C in tripartate buffer [0.1 M 2-(*N*-morpholino)ethanesulfonic acid (MES), 0.051 M *N*-

ethylmorpholine, 0.051 M diethanolamine, pH 8.3] (Ellis & Morrison, 1982). The values presented here are the average of at least three independent assays.

Data Analysis

All collected data were fit with TableCurve 2D, and the equation for the linear regression line with maximal r^2 value (square of the Pearson product moment correlation coefficient) was selected. The V_{\max} and $[\text{Asp}]_{0.5}$ were calculated directly from these equations. The n_H values were determined from a Hill plot of the data.

RESULTS

Sequence Analysis of the Ec and Sm Native Enzymes

On the basis of the extensive sequencing of the Sm *pyrBI* operon performed in this study, ten corrections to the published amino acid sequence (Beck et al., 1989) were confirmed (Table 1). Eight corrections were made in the catalytic polypeptide, and the number of residue differences between Sm and Ec enzymes was increased from 38 to 46. Two corrections were made in the S5' β -strand of the regulatory polypeptide, and the number of residue differences in the regulatory polypeptide was increased from 35 to 37. Consequently, the amino acid similarities were 85% of the catalytic polypeptide and 76% for the regulatory polypeptide (Figure 3).

Kinetic Analysis of Native and Chimeric Enzymes

The maximal reaction velocities (V_{\max}) of all three enzymes were similar (Table 2 and Figure 4). However, the patterns of V_{\max} due to the presence of different nucleotide effectors varied between the enzymes. The ATP-liganded Ec enzyme had the same V_{\max} as the unliganded enzyme, while CTP and CTP plus UTP (C + U) both reduced the V_{\max} relative to that of the unliganded enzyme. With the Sm holoenzyme, ATP, CTP, and CTP + UTP all increased the V_{\max} , although to different extents. This was also true for the chimera where, even though CTP and C + U had been converted to inhibitor, all nucleotide effectors still increased the V_{\max} relative to the unliganded form. UTP alone had no significant effect on any of the three enzymes.

The various nucleotide effectors influenced the $[\text{Asp}]_{0.5}$ of each enzyme, consistent with their allosteric roles. CTP increased the $[\text{Asp}]_{0.5}$ of both the native Ec and chimeric enzymes, while it reduced $[\text{Asp}]_{0.5}$ of the native Sm enzyme. For all these enzymes, the addition of UTP increased the $[\text{Asp}]_{0.5}$ of the CTP-liganded enzymes (see Table 2). Overall, the $[\text{Asp}]_{0.5}$ of the SM:rS5'ec chimeric enzyme was much lower than the values of either of the native enzymes (Table 2). ATP induced a lower $[\text{Asp}]_{0.5}$, consistent with its role as an activator, while CTP increased the $[\text{Asp}]_{0.5}$, consistent with its role as an inhibitor. UTP alone did not show much effect, but in the presence of CTP, UTP dramatically increased the $[\text{Asp}]_{0.5}$.

The Ec enzyme exhibited homotropic cooperativity, as measured by the Hill coefficient, which was reduced by ATP and enhanced by CTP. In contrast, the n_H of the native Sm enzyme was increased significantly in the presence of either ATP or CTP (both activators). The Ec pattern is consistent with the idea that inhibitors shift the enzyme population toward the T-state, thus making it more difficult to induce the active form of the enzyme, resulting in an increase in cooperativity. The converse would be true for activation, resulting in a decrease in n_H . The S5' β -strand substitution converted the Sm ATCase to Ec-like cooperativity with the n_H value of the chimera being decreased in the presence of activator (ATP) and increased in the presence of inhibitor (CTP).

Allosteric Regulation by Individual Nucleotides

In order to determine the relative sensitivity of each enzyme to the various nucleotides, the specific activities were determined under increasing concentrations of nucleotide effector (Figure 5A,B). The maximum activation of the native Sm enzyme was not completely reached until 10 mM ATP, and the reaction rate was three times higher than that in the absence of nucleotide effector at the $[\text{Asp}]_{0.5}$. Similarly, the activity of the native Sm enzyme was almost doubled by the presence of 2 mM CTP (Figure 5A). In contrast, high concentrations of ATP induced only a 68% enhancement of the native Ec enzymatic activity, while CTP reduced the activity of the native Ec enzyme by 50% (Figure 5B). Even though it appeared that a high concentration of UTP (10 mM) had a slight inhibitory effect, this inhibition was reversible by doubling the CP concentration, indicating that UTP could be binding to the active site and competitively inhibiting the enzymatic activity. Increasing the CP concentration had no observable effect in other effector studies. In the chimeric enzyme, ATP still functioned as a modest activator, while the CTP response was converted to inhibition, characteristic of the Ec enzyme (Figure 5).

Allosteric Effector Interactions

In order to evaluate the allosteric effects of combinations of nucleotides, competition assays were performed by increasing concentrations of one nucleotide in the presence of saturating concentrations of a second nucleotide. With the native Sm ATCase, in spite of the fact that ATP and CTP both functioned as strong activators, CTP was not capable of additional stimulation in the presence of 2 mM ATP. Surprisingly, this was also true of ATP in the presence of CTP (Figure 6A). In contrast, the enhanced level of enzymatic activity of the Ec enzyme in the presence of 2 mM ATP was reversed by as little as 0.1 mM CTP. The inhibition by CTP was also reversed by a high concentration of ATP (Figure 6B). In the native Sm ATCase, UTP counteracted the stimulatory effect of ATP, although it could not completely eliminate activation (Figure 7A). With the Ec ATCase, there was no indication of any ATP/UTP competition or synergism (Figure 7B), but the enzyme did exhibit the UTP/CTP synergistic inhibition (Figure 8B) as previously described (Wild et al., 1989). A partial competition between these nucleotides occurred in the Sm enzyme, but there was no indication of the synergism seen with the native Ec enzyme.

All of the CTP-associated interactions of the parental Sm ATCase were converted to the Ec patterns in the chimeric enzyme. ATP successfully competed with CTP in the Ec and the chimeric enzymes but not in the native Sm enzyme (Figure 6). This was also observed for the UTP/CTP competition, where UTP competed with CTP for activation in the native Sm enzyme, while the combination synergistically inhibited both the chimeric Sm enzyme and the native Ec enzyme (Figure 8). In contrast, the chimeric enzyme retained the UTP/ATP response pattern of the native Sm enzyme as UTP successfully competed with ATP activation in both chimeric and native Sm enzymes, while UTP had no effect on the ATP-liganded Ec enzyme (Figure 7). A summary of the allosteric patterns of the native and chimeric enzymes is presented in Table 3.

DISCUSSION

The Role of Comparative Sequence Analysis in Establishing Structure–Function Hypotheses of ATCase

Site-directed mutagenesis studies commonly rely on an interpretation of structures provided by X-ray diffraction analyses of protein crystals. However, functional changes may be based on subtle differences in secondary or supersecondary structures which cannot be detected by the refinement of the diffraction data. In such cases, the functional variations among homologous proteins provide a unique opportunity for the formulation and analysis of

structure–function hypotheses. In these studies, the selection of structural regions to be analyzed was based on information provided by the comparative analysis of the amino acid sequences of the ATCases from the Ec and Sm enzymes (Shanley et al., 1984; Foltermann et al., 1984, 1986; Beck et al., 1989; Wild et al., 1990). Hybrid enzymes constructed with subunits isolated from the different bacterial species had previously demonstrated that the pattern of allosteric control was exclusively determined by the regulatory subunits (Beck et al., 1989; Shanley et al., 1984; Wild et al., 1990; Wales & Wild, 1991).

Of the 153 residues of the Ec regulatory subunit, only 37 varied between the Ec and Sm enzymes (Figure 3). Almost half of these diverged residues are clustered in the 100's region (r93–r105, located between the allosteric and the zinc domains, 8 differences out of 13 amino acids) and the 130's region (r126–r135, which is involved in the r1:c1 interface, 8 differences out of 10 amino acids). When this sequence information was combined with structural information provided by X-crystallography (Gouaux et al., 1990; Stevens et al., 1990; Ke et al., 1988; Kosman et al., 1993), it was observed that the S5' β -strand, which connects the nucleotide binding site to the zinc domain through the r98–r101 loop, was the only structural feature in the regulatory polypeptide which was not extensively conserved. This study clearly demonstrates the importance of the S5' β -strand region in the allosteric modulation of CTP and CTP + UTP synergistic effects of ATCase.

The Native Enzymes Have Diverged Dramatically in both Their Catalytic and Their Allosteric Characteristics

In spite of the architectural similarities of the two native enzymes, the Sm and Ec ATCases differ in most of their homotropic and heterotropic characteristics as reported in Results. However, the most notable differences were found within the patterns of NTP allosteric response. The EC ATCase regulatory logic is one of the paradigms of allosteric regulation: activation by ATP, inhibition by CTP, and synergistic inhibition by CTP and UTP. In contrast, the Sm enzyme is activated by both ATP and CTP, and there is no evidence of CTP/UTP synergism under the conditions used in this study (Figure 8). The logic of this regulatory pattern requires an appreciation for the levels of intracellular pools of these nucleotides and the resulting competition that occurs as a consequence of competition for a common binding site. In Sm and Ec, the intracellular pool of ATP is about five times greater than that of CTP (Wild et al., 1988), and the regulatory logic is that the ATP-activated enzyme is rendered less active (inhibited) as a result of competition with CTP, regardless of the independent allosteric effects of the diverged ATCases.

This logic is demonstrated in the nucleotide competition studies with the Sm enzyme, in which CTP competed with ATP, effectively lowering the activity of the ATP-activated state (Wild et al., 1989; this study). Consistent with the apparent lower affinity of the enzyme for ATP, ATP did not exert a comparable effect on the CTP-activated enzyme. In contrast, there is clear competition between the nucleotides in the Ec enzyme: CTP rapidly reduced the ATP-activated levels to the CTP-inhibited levels, and ATP competed with CTP, even though there is a 10-fold differences in the binding constants between these two nucleotides (Tondre & Hammes, 1974; Allewell et al., 1975; England & Hervé, 1992, 1994). Similar differences were seen in other nucleotide competition studies. ATP and UTP successfully competed with each other in the Sm enzyme. However, in the Ec ATCase, UTP did not appear to have any effect on the ATP-liganded enzyme. The CTP/UTP synergism of the Ec enzyme was apparent in the CTP and UTP competition studies, and although there was no evidence of synergism, CTP and UTP did compete with each other in the Sm enzyme. Equilibrium binding and continuous flow dialysis have provided an explanation for the Ec synergism such that the Ec holoenzyme contains two classes of allosteric sites, as defined by their binding affinities. The binding of CTP to one allosteric site decreases the affinity of the second site for this nucleotide but increases its affinity for UTP. Conversely, the binding of

UTP to one of the two sites decreases the affinity of the second site for this nucleotide but increases the affinity for CTP (Zhang & Kantrowitz, 1991; England & Hervé, 1992). This same explanation cannot be applied to the ATCase of Sm in which the activation by CTP was only counteracted by increased concentrations of UTP. If the Sm enzyme followed the Ec pattern of allosteric site cooperativity, the CTP effect (activation in this case) should be amplified in the presence of UTP. Even though the $[CTP]_{0.5}$ is decreased 10-fold over that of the ATP ($[ATP]_{0.5}/[CTP]_{0.5}$ of 10), ATP can counteract CTP inhibition of the Ec enzyme. However, in spite of a $[ATP]_{0.5}/[CTP]_{0.5}$ ratio of 4, ATP was not able to affect the CTP activation of the Sm enzyme, indicating that a different ATP/CTP interaction exists for the Sm enzyme. Similarly, enzymatic response to other nucleotide interactions has also diverged between the two native enzymes.

The SM:rS5'ec Chimeric Enzyme Displayed the CTP and CTP + UTP Allosteric Responses of the Ec Enzyme

The chimeric SM:rS5'ec enzyme displayed a dramatic decrease in its $[Asp]_{0.5}$ and a reversal of CTP and CTP + UTP allosteric effects relative to the native Sm enzyme. This conversion demonstrated that the S5' β -strand was important in establishing either a unique T:R ratio or a unique R-state. One of the most important consequences of the substitution of the S5' β -strand with the corresponding Ec sequence is the dramatic reduction of the $[Asp]_{0.5}$. This may indicate that the enzyme has converted to a new R conformation or has established a new T:R ratio (a structural verification awaits additional studies). Even though the structure of the Sm has not yet been determined, these results suggest that the S5' β -strand plays a critical role in defining the conformational state of the enzyme.

In addition to the dramatic decrease in the $[Asp]_{0.5}$, the SM:rS5'ec enzyme has assumed the Ec pattern of allosteric regulation in all responses involving CTP such that CTP became an inhibitor, CTP/UTP synergism was established, and CTP/ATP competition was restored (Table 3). Even though both ATP and CTP are activators in the Sm enzyme, only the CTP effect was reversed. However, while ATP still functioned as an activator of the chimeric enzyme, the ATP-activated level was dramatically reduced as compared with the Sm native enzyme. The transmission and polarity of the ATP signal are determined separately from the CTP or CTP/UTP inhibitory effects, and a pathway of residues which mediate the Ec ATP response has been proposed (Van Vliet et al., 1991; De Staercke et al., 1995; Xi et al., 1994). These Ec studies predict that the correct transmission of the ATP signal requires an appropriate separation of the allo and Zn domains and that this separation (or coupling) is modulated at the hydrophobic interface (see Figure 1B). There are a number of proposals concerning the Ec ATCase allosteric mechanism in the literature (Krause et al., 1993; Allewell, 1989; Lipscomb, 1994; De Staercke et al., 1995; Xi et al., 1994). One feature in common to these proposals is a reliance on the coupling between the Zn and allo domains and its modulation by the binding of the nucleotide effectors.

Alternatively, thermodynamic analysis of the allosteric phenomenon in other enzymes has been offered by Reinhart and colleagues (Braxton et al., 1994, 1996). The role played by entropy relative to the change in free energy of the allosteric phenomenon was studied using the temperature dependence of the allosteric equilibrium. This thermodynamic-linked function provides an additional consideration in the analysis of allosteric enzymes. Preliminary investigations of ATCase upon temperature shifts from 15 to 45 °C indicate that entropy changes did affect the extent of activation or inhibition but did not change the allosteric polarity in the Ec enzyme.

The S5' β -strand of the regulatory polypeptide has been identified as critical to the allosteric responses of ATCase, and its physical location at the outer surface of a five-stranded β -sheet of the allosteric domain directly links the allo domain with the Zn domain (Figure 1). In this

position, the S5' β -strand is optimally located to play a role in signal transduction. While the change in the overall pattern of allosteric responses in the SM:rS5'ec enzyme suggests that there may be a global mechanism, whether chemical or physical, linking all of the nucleotide responses, a description of the allosteric mechanism as a discrete pathway of residues for each signal may be too simplistic.

References

- Allewell NM. *Annu Rev Biophys Chem*. 1989; 18:71–92. [PubMed: 2660834]
- Allewell NM, Friedland J, Niekamp K. *Biochemistry*. 1975; 14:224–230. [PubMed: 235271]
- Beck DA, Kedzie KM, Wild JR. *J Biol Chem*. 1989; 264:16629–16637. [PubMed: 2674139]
- Bethell MR, Smith KE, White JS, Jones ME. *Proc Natl Acad Sci USA*. 1968; 60:1442–1449. [PubMed: 4877273]
- Braxton BL, Tlapak-Simmons VL, Reinhart GD. *J Biol Chem*. 1994; 269:47–50. [PubMed: 8276837]
- Braxton BL, Mullins LS, Raushel FM, Reinhart GD. *Biochemistry*. 1996; 35:11918–11924. [PubMed: 8794775]
- Deng WP, Nickoloff JA. *Anal Biochem*. 1992; 200:81–88. [PubMed: 1595905]
- De Staercke C, Van Vliet F, Xi G, Rani CS, Ladjimi M, Jacobs A, Triniolles F, Hervé G, Cunin R. *J Mol Biol*. 1995; 246:132–143. [PubMed: 7853393]
- Ellis KJ, Morrison JF. *Methods Enzymol*. 1982; 87:405–426. [PubMed: 7176924]
- England P, Hervé G. *Biochemistry*. 1992; 31:9725–9732. [PubMed: 1390749]
- England P, Hervé G. *Biochemistry*. 1994; 33:3913–3918. [PubMed: 8142394]
- Foltermann KF, Shanley MS, Wild JR. *J Bacteriol*. 1984; 157:891–898. [PubMed: 6365893]
- Foltermann KF, Beck DA, Wild JR. *J Bacteriol*. 1986; 67:285–290. [PubMed: 3722124]
- Gerhart JC, Pardee AB. *J Biol Chem*. 1962; 237:891–896. [PubMed: 13897943]
- Gerhart JC, Holoubek H. *J Biol Chem*. 1967; 242:2886–2892. [PubMed: 5338508]
- Gerhart JC, Schachman HK. *Biochemistry*. 1968; 7:538–552. [PubMed: 4868540]
- Gouaux JE, Lipscomb WN. *Biochemistry*. 1990; 29:389–402. [PubMed: 2405902]
- Gouaux JE, Stevens RC, Lipscomb WN. *Biochemistry*. 1990; 29:7702–7715. [PubMed: 2271529]
- Jones ME, Spector L, Lipmann F. *J Am Chem Soc*. 1955; 77:819–820.
- Kantrowitz ER, Lipscomb WN. *Trends Biochem Sci*. 1990; 15:53–59. [PubMed: 2186515]
- Ke HM, Lipscomb WN, Cho Y, Honzatko RB. *J Mol Biol*. 1988; 204:725–747. [PubMed: 3066911]
- Kosman RP, Gouaux JE, Lipscomb WN. *Proteins: Struct, Funct, Genet*. 1993; 15:147–176. [PubMed: 8441751]
- Krause KL, Volz KW, Lipscomb WN. *J Mol Biol*. 1987; 193:527–553. [PubMed: 3586030]
- Lipscomb WN. *Adv Enzymol*. 1994; 68:67–151. [PubMed: 8154326]
- Nowlan SF, Kantrowitz ER. *J Biol Chem*. 1985; 260:14712–14716. [PubMed: 3902838]
- Prescott LM, Jones ME. *Anal Biochem*. 1969; 32:408–419. [PubMed: 5361395]
- Reichard P, Hanshoff G. *Acta Chem Scand*. 1956; 10:548–566.
- Roof WD, Foltermann KF, Wild JR. *Mol Gen Genet*. 1982; 187:391–400. [PubMed: 6294470]
- Sasse, J. *Current Protocols in Molecular Biology*. Ausubel, FM., et al., editors. Vol. 2. Greene Publishing Associates and Wiley-Interscience; New York: 1988. p. 10.6.1–10.6.3.
- Schachman HK. *J Biol Chem*. 1988; 263:18583–18586. [PubMed: 3058687]
- Shanley MS, Foltermann KF, O'Donovan GA, Wild JR. *J Biol Chem*. 1984; 259:12672–12677. [PubMed: 6386799]
- Smith, JA. *Current Protocols in Molecular Biology*. Ausubel, FM., et al., editors. Vol. 2. Greene Publishing Associates and Wiley-Interscience; New York: 1988. p. 10.2.1–10.2.9.
- Stevens RC, Gouaux JE, Lipscomb WN. *Biochemistry*. 1990; 29:7691–7701. [PubMed: 2271528]
- Stevens RC, Chook YM, Cho CY, Lipscomb WN, Kantrowitz ER. *Protein Eng*. 1991; 4:391–408. [PubMed: 1881865]
- Tondre C, Hammes GG. *Biochemistry*. 1974; 13:3131–3136. [PubMed: 4601429]

- Van Vliet F, Xi XG, De Staercke C, De Wannemaeker B, Jacobs A, Cherfils J, Ladjimi MM, Hervé G, Cunin R. *Proc Natl Acad Sci USA*. 1991; 88:9180–9183. [PubMed: 1924381]
- Wales ME, Hoover TA, Wild JR. *J Biol Chem*. 1988; 263:6109–6114. [PubMed: 3283120]
- Wild JR, Wales ME. *Annu Rev Microbiol*. 1990; 44:193–218. [PubMed: 2252382]
- Wild JR, Foltermann KF, Loughreychen SJ, O'Donovan GA. *Arch Biochem Biophys*. 1980; 201:506–517. [PubMed: 7396519]
- Wild JR, Johnson JL, Loughrey SJ. *J Bacteriol*. 1988; 170:446–448. [PubMed: 3275626]
- Wild JR, Loughreychen SJ, Corder TS. *Proc Natl Acad Sci USA*. 1989; 86:46–50. [PubMed: 2643106]
- Wild, JR.; Grimsley, JK.; Kedzie, KM.; Loughreychen, SJ.; Wales, ME. *Chemical Aspects in Enzyme Biotechnology*. Baldwin, TO., et al., editors. Plenum Press; New York: 1990. p. 95-109.
- Xi XG, De Staercke C, Van Vliet F, Triniolles F, Jacobs A, Stas PP, Ladjimi MM, Simon V, Cunin R, Hervé G. *J Mol Biol*. 1994; 242:139–149. [PubMed: 8089837]
- Zhang Y, Kantrowitz ER. *J Biol Chem*. 1991; 266:22154–22158. [PubMed: 1939236]




Figure 1.

(A, top) Molecular graphic representation of a CTP-liganded R-state holoenzyme of ATCase from *Ec*. The holoenzyme is composed of two catalytic trimers (one trimer is shown in blue while the second is located beneath this trimer and not shown here for the purpose of simplification) and three regulatory dimers (in yellow). The nucleotide effector CTP (in white sticks and purple balls) binds on the allosteric domain and exerts its effect through the zinc domain (six zinc atoms are indicated as white balls) to the catalytic sites 60 Å away [the catalytic site lies between the Asp and CP domains of each catalytic monomer and is defined by the substrate analogs phosphoacetamide (purple balls) and malonate (yellow balls)]. The substituted regions (r93–r97, red ribbon) are located at the junction between the allosteric binding sites and the catalytic sites. (B, bottom) The α -Carbon trace of a regulatory dimer is shown in yellow. The altered $S5'$ β -strand regions (r93–r97) are shown in red; the CTP nucleotide effectors in purple occupy the allosteric binding site; and the hydrophobic pockets (green) are located at the interface of the allosteric and zinc domains. All atomic coordinates are originally from file “8at1.full” in the Protein Data Bank supplied by Gouaux et al. (1990).

```

      H1      H1
E. coli  WYDNLQGV ALRQSPVIR IFAQTTEEL KEHALWETQ 40
S. marcescens WYDNLQGV ALRQSPVIR IFAQLGKEL PLFLATKQ 40
      S2      S2
E. coli  RITTELRGG GSRDTEELT TTRPFLARDV VRLKADVAG 80
S. marcescens RITTELRGG GSRDTEELT TTRPFLARDV VRLKADVAG 80
      S3      S3
E. coli  AVYGLDYS VYRPFELD ERLQVLYCT ESRGIRKADP 120
S. marcescens AVYGLDYS VYRPFELD ERLQVLYCT ESRGIRKADP 120
      S4      S4
E. coli  VRSDFVRS GSRVLELCKI CDSDFRQVY LQAD 153
S. marcescens VRSDFVRS GSRVLELCKI CDSDFRQVY LQAD 154

```

Figure 2.

Comparison of the amino acid sequence of the regulatory polypeptides between Ec and Sm ATCase. The standard single-letter abbreviations from the amino acids are used. The presence of a “.” indicates a shift in sequence to optimize the alignments. The residues in bold are those which differ between the Ec and Sm ATCases. The lines above the sequence correspond to the secondary structural elements as determined for the Ec enzyme with H representing α -helices and S representing β -strands. Each structural element is numbered sequentially with the “” indicating its location in the regulatory polypeptide. The S5' β -strand is comprised in its entirety by the altered region (r93–r97).

Catalytic Chain

MANPLYHKHI	ISINDLSRE D	L ELVLR TAAG	LKANPQPELL	KHKVIASCFF	50
EASTRTRLSF	ETSMHRLGAS	VVG FAD GSNT	SLGKKGETLA	DTISVISTYV	100
DAIVMRHPQE	GAAM ASEFSG	NVPV LN AGDG	NQHPTQ TLLD	LFTIQETQGR	150
LSNLSIAMVG	DLKYGRTVHS	LTQALAKFEG	NRFYFIAPDA	LAMPAYILKM	200
LEEKGIEY SL	HGSIEEVVPE	LDILY MTR VQ	KERLDPSEYA	NVKAQFVLAA	250
DLAGAANLKV	LHPLPRIDEI	ATD VDK TPHA	YYFQQAGNGI	FARS GCWLV L	300
NADLAL					306

Regulatory Chain

MTHDNKLQVE	AIKCGTVIDH	IPAQIGFKLL	TLFKLTATDQ	RITIGLNLPS	50
NELGRKDLIK	I ENT FLTEQQ	ANQLAMYAPK	ATVNRIDN YE	VVR NVT LSLP	100
DHIDGVLTCP	NGNCISRSEP	VRSSFSVKSR	GGEVHLKCRY	CEKEFEHQVV	150
LQAD					154

Figure 3.

Amino acid sequence of the catalytic and regulatory polypeptides of *S. marcescens* ATCase. The bold letters represent those amino acids which have been corrected as compared with the data published by Beck et al. (1989).




Figure 4. Aspartate saturation kinetics in the presence of nucleotide effectors for native Sm (A), native Ec (B), and chimera SM:rS5'ec (C) ATCase holoenzyme. The aspartate saturation of ATCase activity was determined in the presence of (□) either 4 mM (for the native Sm enzyme) or 2 mM ATP (for the native Ec enzyme and the chimeric enzyme, respectively), (Δ) 2 mM CTP, (▽) 2 mM UTP, (◇) 2 mM CTP plus 2 mM UTP, and (○) without any nucleotide effector. Standard assay conditions were used, and each curve is the average of at least three independent assays.




Figure 5.

Comparative nucleotide saturation kinetics of native Sm (A), native Ec (B), and chimera SM:rS5'ec (C) ATCase holoenzyme. The saturation effects of ATP (●), CTP (■), and UTP (▲) on the activity of ATCase were determined under assay conditions employing saturating carbamoyl phosphate concentrations and aspartate concentrations at the $[\text{Asp}]_{0.5}$ of each enzyme (4.8 mM carbamoyl phosphate for all enzymes; 39.2, 16.6, and 4.7 mM aspartate for native Sm, Ec, and chimera SM:rS5'ec enzymes, respectively). The specific activity was measured at each concentration of nucleotide (NTP) and plotted relative to the activity with no effector present.




Figure 6. ATP and CTP saturation curves in the presence of 2 mM CTP or 2 mM ATP as compared to the one in the absence of other nucleotide effectors for native Sm (A), native Ec (B), and chimera SM:rS5'ec (C) ATCase holoenzyme. The saturation kinetics of the effects of varying ATP (●), varying ATP in the presence of CTP (○), varying CTP (■), and varying CTP in the presence of ATP (□) on the activity of ATCase were determined in the same way as described in Figure 5.




Figure 7.

ATP and UTP saturation curves in the presence of 2 mM UTP or 2 mM ATP as compared to the one in the absence of other nucleotide effectors for native Sm (A), native Ec (B), and chimera SM:rS5'ec (C) ATCase holoenzyme. The saturation kinetics of the effects of varying ATP (●), varying ATP in the presence of UTP (○), varying UTP (■), and varying UTP in the presence of ATP (□) on the activity of ATCase were determined in the same way as described in Figure 5.




Figure 8. CTP and UTP saturation curves in the presence of 2 mM UTP or 2 mM CTP as compared to the one in the absence of other nucleotide effectors for native Sm (A), native Ec (B), chimera SM:rS5'ec (C) ATCase holoenzyme. The saturation kinetics of the effects of varying CTP (●), varying CTP in the presence of UTP (○), varying UTP (■), and varying UTP in the presence of CTP (□) on the activity of ATCase were determined in the same way as described in Figure 5.

Table 1

Corrections to the Amino Acid Sequence Published by Beck et al. (1989)

position	original		corrected	
	amino acid	codon	amino acid	codon
c19	D	GAC	E	GAG
c26	A	GCG	R	CGC
c113	R	CGC	A	GCG
c210	S	TCG	L	CTG
c295	A	GCC	G	GGC
c296	L	TTG	C	TGC
c297	A	GCG	W	TGG
c300	V	GTC	L	CTC
r94	K	AAG	N	AAC
r95	L	CTG	V	GTG

Table 2

Kinetic Parameters of the Native and Chimeric Form of ATCase^a

	nucleotide effectors ^b				
	none	ATP	CTP	UTP	C + U
Native Sm Holoenzyme					
V_{\max}^c	22.4 ± 0.5	25.6 ± 1.2	25.0 ± 0.4	23.1 ± 0.6	30.2 ± 0.4
[Asp] _{0.5} ^d	39.2 ± 0.3	17.7 ± 3.7	22.0 ± 1.8	41.0 ± 3.1	25.7 ± 1.0
n_H^e	1.9 ± 0.1	2.5 ± 0.1	2.7 ± 0.1	2.2 ± 0.1	2.2 ± 0.1
[NTP] _{0.5} ^f	ud ^g	1.8	0.5	ud	nd ^h
Native Ec Holoenzyme					
V_{\max}	24.9 ± 1.2	24.8 ± 0.6	18.9 ± 1.9	25.1 ± 0.2	16.7 ± 0.5
[Asp] _{0.5}	16.6 ± 1.4	9.9 ± 1.9	27.3 ± 2.0	15.4 ± 2.7	31.8 ± 2.0
n_H	3.2 ± 0.1	2.5 ± 0.3	3.7 ± 0.5	3.1 ± 0.3	3.1 ± 0.2
[NTP] _{0.5}	ud	1.0	0.1	ud	nd
Chimera SM:rS5'ec Holoenzyme					
V_{\max}	18.5 ± 1.1	25.0 ± 0.6	25.5 ± 0.3	25.9 ± 0.4	23.8 ± 0.5
[Asp] _{0.5}	4.7 ± 0.1	2.8 ± 0.1	9.0 ± 0.4	4.6 ± 0.1	12.0 ± 1.2
n_H	2.1 ± 0.1	1.5 ± 0.1	2.5 ± 0.2	2.2 ± 0.1	2.2 ± 0.1
[NTP] _{0.5}	ud	0.3	0.2	ud	nd

^a All assays were carried out in the tripartate buffer (pH 8.3).^b The values of V_{\max} , [Asp]_{0.5}, and n_H were determined at a nucleotide effector concentration of 2 mM. The single exception was ATP, which was 4 mM in the assays with the native Sm holoenzyme.^c Maximal velocity, estimated at saturating concentrations of substrate, is given as micro-moles per hour per milligram.^d Concentration of aspartate (mM) required to produce half-maximal velocity.^e Hill coefficient (n_H) estimated from aspartate saturation kinetics (determined by the Hill plot).^f [NTP]_{0.5} is the nucleotide concentration (mM) at which the nucleotide exhibits half of its maximum effect. The values were calculated from Figure 5.^g ud indicates the value is unable to be determined.^h nd indicates the value is not determined.

Table 3

Allosteric Patterns of the Native and Chimeric Enzymes

nucleotide effectors ^a	Sm	Ec	SM:rS5'ec
Pattern Common for Three Enzymes			
ATP	+++ ^b	++	+
UTP	0	0	0
CTP/ATP	±	±	±
ATP/UTP	±	±	±
Pattern Common for Native Ec and Chimera			
CTP	+++	-	-
ATP/CTP	0	±	±
CTP/UTP	±	=	=
UTP/CTP	±	=	=
Pattern Common for Native Sm and Chimera			
UTP/ATP	±	0	±

^aIn the paired nucleotide studies, the first nucleotide listed was used at increasing concentration in the presence of a certain concentration of the second listed nucleotide. For example, ATP/CTP indicates varying concentrations of ATP in the presence of a saturating concentration of CTP; CTP/ATP indicates varying concentrations of CTP in the presence of a saturating concentration of ATP.

^b+++ represents strong activation; ++, activation; +, weak activation; 0, no effect; -, inhibition; =, synergistic inhibition; ±, competition.